These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

106 related items for PubMed ID: 1699272

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Two randomised and placebo-controlled studies of an oral prostacyclin analogue (Iloprost) in severe leg ischaemia. The Oral Iloprost in severe Leg Ischaemia Study Group.
    Eur J Vasc Endovasc Surg; 2000 Oct; 20(4):358-62. PubMed ID: 11038148
    [Abstract] [Full Text] [Related]

  • 3. [Iloprost, a stable prostacyclin derivative, in stage 4 arterial occlusive disease. A placebo-controlled multicenter study].
    Diehm C, Abri O, Baitsch G, Bechara G, Beck K, Breddin HK, Brock FE, Clevert HD, Corovic D, Marshall M.
    Dtsch Med Wochenschr; 1989 May 19; 114(20):783-8. PubMed ID: 2470569
    [Abstract] [Full Text] [Related]

  • 4. Oral iloprost treatment in patients with Raynaud's phenomenon secondary to systemic sclerosis: a multicenter, placebo-controlled, double-blind study.
    Wigley FM, Korn JH, Csuka ME, Medsger TA, Rothfield NF, Ellman M, Martin R, Collier DH, Weinstein A, Furst DE, Jimenez SA, Mayes MD, Merkel PA, Gruber B, Kaufman L, Varga J, Bell P, Kern J, Marrott P, White B, Simms RW, Phillips AC, Seibold JR.
    Arthritis Rheum; 1998 Apr 19; 41(4):670-7. PubMed ID: 9550476
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Outpatient treatment of severe peripheral ischemia with intravenous intermittent low-dose iloprost. An open pilot study.
    Banyai S, Jenelten R, Wagner S, Allmann J, Banyai M, Koppensteiner R.
    Int Angiol; 2002 Mar 19; 21(1):36-43. PubMed ID: 11941272
    [Abstract] [Full Text] [Related]

  • 7. [The role of iloprost in the treatment of critical ischemia of the limbs].
    Poggesi L, Comeglio M.
    Ann Ital Med Int; 1993 Oct 19; 8 Suppl():71S-77S. PubMed ID: 7509614
    [Abstract] [Full Text] [Related]

  • 8. Clinical and circulatory effects of Iloprost either administered for 1 week or 4 weeks in patients with peripheral obstructive arterial disease at Leriche-Fontaine stage III.
    Arosio E, Sardina M, Prior M, De Marchi S, Zannoni M, Bianchini C.
    Eur Rev Med Pharmacol Sci; 1998 Oct 19; 2(2):53-9. PubMed ID: 10229559
    [Abstract] [Full Text] [Related]

  • 9. Is it possible to improve outcome in patients undergoing surgery for acute limb ischemia? Can iloprost, a prostacyclin analogue, be helpful?
    de Donato G, Gussoni G, de Donato G.
    Chir Ital; 2004 Oct 19; 56(6):769-80. PubMed ID: 15771029
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Low-dose iloprost infusions compared to the standard dose in patients with peripheral arterial occlusive disease Fontaine stage IV. DAWID Study Group.
    Beischer W, Dembski JC, Gruss JD, Hofgärtner F, Horsch A, Horsch S, Kuhlmann HW, Loose DA, Mietaschk A, Schwilden ED, Spengel F, Spitzer W, Staben P, Stallkamp B, Stürzebecher CS, Tokhi M, von Bilderling P.
    Vasa; 1998 Feb 19; 27(1):15-9. PubMed ID: 9540427
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Efficacy and safety of mixed amphetamine salts extended release (Adderall XR) in the management of attention-deficit/hyperactivity disorder in adolescent patients: a 4-week, randomized, double-blind, placebo-controlled, parallel-group study.
    Spencer TJ, Wilens TE, Biederman J, Weisler RH, Read SC, Pratt R.
    Clin Ther; 2006 Feb 19; 28(2):266-79. PubMed ID: 16678648
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. [Critical ischemia in elderly patients. Evaluation of the effect of two different methods of Iloprost therapy on the efficacy, tolerance, modification of quality of life and self-sufficiency].
    Cappelli R, Bicchi M, Arrigucci S, Boschi S, Guerrini M, Forconi S.
    Minerva Cardioangiol; 1999 Mar 19; 47(3):81-8. PubMed ID: 10389449
    [Abstract] [Full Text] [Related]

  • 18. Evaluation of a conservative treatment with iloprost in severe peripheral occlusive arterial disease (POAD). GISAP Study.
    Int Angiol; 1994 Mar 19; 13(1):70-4. PubMed ID: 7521384
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.